The role of CRISPR-Cas9 and CRISPR interference technologies in the treatment of autoimmune diseases

被引：0
作者：
Khademi, Zahra [1 ,2 ,4 ]
Mottaghi-Dastjerdi, Negar [3 ,4 ]
Morad, Hamed [4 ,5 ]
Sahebkar, Amirhossein [4 ,6 ,7 ,8 ]
机构：
[1] Shiraz Univ Med Sci, Ctr Nanotechnol Drug Delivery, Shiraz, Iran
[2] Shiraz Univ Med Sci, Sch Pharm, Dept Pharmaceut Nanotechnol, Shiraz, Iran
[3] Iran Univ Med Sci, Sch Pharm, Dept Pharmacognosy & Pharmaceut Biotechnol, Tehran, Iran
[4] Univ Madras, Chennai, India
[5] Iran Univ Med Sci, Sch Pharm, Dept Pharmaceut & Pharmaceut Nanotechnol, Tehran, Iran
[6] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Biotechnol Res Ctr, Mashhad, Iran
[7] Chitkara Univ, Ctr Res Impact & Outcome, Rajpura 140417, Punjab, India
[8] Mashhad Univ Med Sci, Appl Biomed Res Ctr, Mashhad, Iran
来源：
AUTOIMMUNITY REVIEWS | 2025年 / 24卷 / 07期
关键词：
CRISPR-Cas9; CRISPRi; Gene editing; Autoimmunity; Inflammatory bowel disease; Type 1 diabetes mellitus; Precision medicine; Immunotherapy; Gene therapy; Genome engineering; Immune modulation; INFLAMMATORY-BOWEL-DISEASE; ANTI-TNF THERAPY; GENE-THERAPY; BIOLOGIC THERAPIES; CELIAC-DISEASE; BETA-CELL; GENOME; ASSOCIATION; ACTIVATION; STRATEGIES;
D O I：
10.1016/j.autrev.2025.103816
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Autoimmune disorders can be described as inappropriate immune responses directed against self-antigens, which account for substantial healthcare concerns around the world. Immunosuppression or immune modulation are the main therapeutic modalities for autoimmune disorders. These modalities, however, impair the ability of the immune system to fight against infections, thereby predisposing to opportunistic diseases. This review explores existing therapies for autoimmune disorders, highlighting their limitations and challenges. Additionally, it describes the potential of CRISPR-Cas9 technology as a novel therapeutic approach to address these challenges.
引用
收藏
页数：12
相关论文
共 139 条
[1]   IL-15: a central regulator of celiac disease immunopathology [J].
Abadie, Valerie ;
Jabri, Bana .
IMMUNOLOGICAL REVIEWS, 2014, 260 (01) :221-234
[2]   Inflammatory bowel disease: tri-directional relationship between microbiota, immune system and intestinal epithelium [J].
Ahlawat, Shruti ;
Kumar, Pramod ;
Mohan, Hari ;
Goyal, Sandeep ;
Sharma, Krishna Kant .
CRITICAL REVIEWS IN MICROBIOLOGY, 2021, 47 (02) :254-273
[3]   CRISPR/Cas9 Genome-Editing Technology and Potential Clinical Application in Gastric Cancer [J].
Almeida, Renata Sanches ;
Wisnieski, Fernanda ;
Real Karia, Bruno Takao ;
Cardoso Smith, Marilia Arruda .
GENES, 2022, 13 (11)
[4]   9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021 [J].
不详 .
DIABETES CARE, 2021, 44 :S111-S124
[5]   Environmental factors in multiple sclerosis [J].
Ascherio, Alberto .
EXPERT REVIEW OF NEUROTHERAPEUTICS, 2013, 13 (12) :3-9
[6]  
Atkinson MA, 2014, LANCET, V383, P69, DOI [10.1016/S0140-6736(13)60591-7, 10.1016/S0140-6736(18)31320-5]
[7]   Next-generation technologies for studying host-pathogen interactions: a focus on dual transcriptomics, CRISPR/Cas9 screening and organs-on-chips [J].
Baddal, Buket .
PATHOGENS AND DISEASE, 2019, 77 (06)
[8]   Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies [J].
Bar-Or, Amit ;
Pender, Michael P. ;
Khanna, Rajiv ;
Steinman, Lawrence ;
Hartung, Hans-Peter ;
Maniar, Tap ;
Croze, Ed ;
Aftab, Blake T. ;
Giovannoni, Gavin ;
Joshi, Manher J. .
TRENDS IN MOLECULAR MEDICINE, 2020, 26 (03) :296-310
[9]   Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis [J].
Bartok, Beatrix ;
Firestein, Gary S. .
IMMUNOLOGICAL REVIEWS, 2010, 233 :233-255
[10]   CRISPR-Cas-mediated transcriptional modulation: The therapeutic promises of CRISPRa and CRISPRi [J].
Bendixen, Louise ;
Jensen, Trine I. ;
Bak, Rasmus O. .
MOLECULAR THERAPY, 2023, 31 (07) :1920-1937
12345678910